Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Cipla has secured USFDA approval to market a generic cancer treatment, specifically paclitaxel protein-bound particles.

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable ...

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.